Given the obvious functional links between PRC1 and PRC2 and the effect that has already been shown on LSC survival by EZH2 inhibition (Scott et al., 2016), perhaps targeting both BMI1 and EZH2 in parallel could have therapeutic potential in CML. The gene discussed is EZH2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.